Hit enter to search or ESC to close


Prana Announces that New York Academy of Sciences eBriefing available online

Prana Biotechnology today announced that the New York Academy of Sciences eBriefing which provides information and video footage of the symposium which took place on November 29th titled “Targeting Metals in Alzheimer’s and Other Neurodegenerative Diseases” is now available for viewing by the public by going to: www.nyas.org/MetalsandAD-eB. The eBriefing features multimedia presentations of speakers’ slides and audio, written meeting summary, and links to related resources.

Prana’s PBT434 Inhibits Accumulation of Parkinson’s protein and Subsequent Death of Brain Cells

Prana Biotechnology today announced that PBT434, Prana’s lead drug candidate for Parkinson’s disease (PD) and movement disorders, will be presented at two international conferences in March. The key finding to be reported is that PBT434 reduces the aggregation and accumulation of a key protein (alpha- synuclein) in multiple transgenic animal models of the disease.

Prana Details Data Showing that PBT2 Reduces Cognitive Impairment Caused by Tau Protein Accumulation

Following on from the announcement released on 4th March, 2013 and at the request of the Australian Securities Exchange, the company is pleased to provide further detail in respect to the presentation of the new data demonstrating the ability of PBT2 to reduce the damage to brain cells, caused by the accumulation of the tau protein and preventing subsequent cognitive impairment.

Prana Provides Clinical Trials Update

Prana Biotechnology today reported on the progress of its lead development asset PBT2 in Phase II trials for Huntington disease and Alzheimer’s disease. Across the two trials approximately 37% have been dosed to 6 months or longer, twice the duration of the previous Phase II Alzheimer’s trial . 1,2 PBT2 has been well tolerated and both trials are on schedule with very pleasing retention rates and compliance. Each Independent Data Safety Monitoring Board for the two trials met at the end of March and recommended that each trial continue as planned without any protocol changes.

Prana Announces RD Refund

Prana Biotechnology today reported that it has received a A$2.5 million cash refund under the R&D Tax Incentive Program, a program administered by AusIndustry and the Australian Taxation Office. This payment is part of approximately $5.8 million expected to be received for the 2011-12 and 2012-13 financial years.

Receive news from Alterity Therapeutics